Table 4 Comparison of clinicopathological features of survivors and non-survivors
From: Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection
Characteristic | Alive (n = 179) | Dead (n = 38) | P value |
|---|---|---|---|
Gender, n (%) | |||
 male | 76 (42.46) | 24 (63.16) | 0.020 |
 female | 103 (57.54) | 14 (36.84) |  |
Age (years), mean ± sd | 56.03 (9.44) | 56.60 (11.39) | 0.742 |
HCV, n (%) | |||
 no | 172 (96.09) | 38 (100) | 0.609 |
 yes | 7 (3.91) | 0 |  |
Platelets ×103 (mm3), median (range) | 192 (57, 568) | 185 (91, 332) | 0.485 |
AFP-pre (ng/mL), median (range), n = 185 | 14.2 (0.89, 82,392) | 115 (1.85, 60,500) | 0.018 |
AFP-post (ng/mL), median (range), n = 125 | 2.8 (0.83, 5271) | 13.11 (1.19, 19,629) | 0.0003 |
Tumor size (cm), median (range), n = 216 | 4.3 (0.5, 26.5) | 5.5 (2, 17) | 0.066 |
  < 5 | 103 (57.54) | 17 (45.95) | 0.196 |
  ≥ 5 | 76 (42.46) | 20 (54.05) |  |
Number of tumors, n (%) | |||
 solitary | 143 (80.79) | 23 (62.16) | 0.013 |
 multiple | 34 (19.21) | 14 (37.84) |  |
Microvascular invasion, n (%) | |||
 no | 141 (79.66) | 29 (78.38) | 0.861 |
 yes | 36 (20.34) | 8 (21.62) |  |
Stage, n (%) | |||
 I | 110 (61.45) | 28 (73.68) | 0.155 |
 II or higher | 69 (38.55) | 10 (26.32) |  |
Resection margin, n (%), n = 185 | |||
 free margin | 144 (96.00) | 32 (91.43) | 0.375 |
 positive margin | 6 (4.00) | 3 (8.57) |  |
Operation type, n (%) | |||
 non-anatomical | 113 (63.13) | 16 (42.11) | 0.017 |
 anatomical | 66 (36.87) | 22 (57.89) |  |
Preoperative neoadjuvant, n (%) n = 164 | |||
 no | 71 (53.79) | 21 (65.63) | 0.226 |
 yes | 61 (46.21) | 11 (34.38) |  |
Platelet-to-lymphocyte ratio, median (range), n = 203 | 101.6 (30.9, 432.8) | 107.1 (51.0, 258.9) | 0.339 |
Prognostic nutritional index, mean ± sd, n = 206 | 97.35 (41.10) | 84.21 (33.78) | 0.082 |
Neutrophil-to-lymphocyte ratio, median (range), n = 201 | 1.73 (0.33, 10.62) | 2 (0.73, 4.41) | 0.298 |
Antiviral treatment | |||
 no | 49 (27.37) | 16 (42.11) | 0.072 |
 yes | 130 (72.63) | 22 (57.89) |  |
Antiplatelet treatment (ASA + Clopidogrel) | |||
 no | 163 (91.06) | 36 (94.74) | 0.746 |
 yes | 16 (8.94) | 2 (5.26) |  |
Recurrence n (%) | |||
 no | 103 (57.54) | 10 (26.32) | 0.000 |
 yes | 76 (42.46) | 28 (73.68) |  |